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We propose a minimal protocol for exhaustive genome-wide association interaction analysis that involves
screening for epistasis over large-scale genomicdata combining strengthsofdifferentmethods and statistical
tools. The different steps of this protocol are illustrated on a real-life data application for Alzheimer’s disease
(AD) (2259 patients and 6017 controls from France). Particularly, in the exhaustive genome-wide epistasis
screening we identiﬁed AD-associated interacting SNPs-pair from chromosome 6q11.1 (rs6455128, the
KHDRBS2 gene) and 13q12.11 (rs7989332, the CRYL1 gene) (p ¼ 0.006, corrected for multiple testing). A
replication analysis in the independent AD cohort from Germany (555 patients and 824 controls) conﬁrmed
the discovered epistasis signal (p ¼ 0.036). This signal was also supported by a meta-analysis approach in 5
independent AD cohorts thatwas applied in the context of epistasis for theﬁrst time. Transcriptome analysis
revealed negative correlation between expression levels of KHDRBS2 and CRYL1 in both the temporal cortex
(b¼0.19,p¼ 0.0006) and cerebellum (b¼0.23,p< 0.0001) brain regions. This is theﬁrst timea replicable
epistasis associated with AD was identiﬁed using a hypothesis free screening approach.
 2014 The Authors. Published by Elsevier Inc. All rights reserved.1. Introduction
Where does heritability hide? This question frequently arises
once heritability is estimated using genetic variants resulting from
a genome-wide association study. Genetic variants for human dis-
ease traits are either rare with hard to quantify population-basedNC-ND license (http://creativecom
niversity of Liège, 10, Grande Tr
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Published by Elsevier Inc. All righeffect sizes, or common, with relatively small or even no individ-
ual effects. Arguably, these effects may be masked or enhanced by
considering additional genomic loci, in other words, by considering
networks of genes (Moore, 2005). Dependencies among genes in
such networks are naturally created by the complexity of gene
regulatory and biochemical networks underlying complex diseasesmons.org/licenses/by-nc-nd/3.0/).
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Fig. 1. Protocol for genome-wide association interaction (GWAI) analysis illustrated on
the AD case and/or control cohort from France. Abbreviation: AD, Alzheimer’s disease.
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(epistasis) (Phillips, 2008). Therefore, incorporating epistasis in
disease association models via genome-wide association interac-
tion (GWAI) studies ﬁts into a systems-level genetics perspective
and is an essential step toward a full understanding of biological
and biochemical disease mechanisms.
Although many examples of biological gene-gene interactions
exist (classical examples of biological epistasis are given in Miko,
2008), its discovery via statistical analysis methods remains a big
challenge. This is in part because of the intrinsic complexity of genetic
architectures associated with human complex diseases; architectures
that are potentially modiﬁed by non-genetic factors as well. Clearly,
additional efforts are needed to develop appropriate and clinically
relevant models that are able to realistically capture the true under-
lying biology. Despite the abundance of approaches developed by the
epistasis community (Van Steen, 2012), their success rate in genome-
wide epistasis studies is fairly low. Ever-returning challenges to take
when performing GWAI studies include adequately dealing with
multiple testing issues, with multicollinearity induced by correlation
patterns between markers, and not in the least, reducing the number
of false positive ﬁndings. Our experience has shown that only by
taking advantages of various methodologies and by examining data
rigorously and comprehensively, hereby adopting a protocol that al-
lows the integration of biological knowledge at various levels of the
analysis process, the intrinsic low power to detect epistasis signals
with currently feasible sample designs can be outweighed.
In this study, we developed a minimal epistasis detection pro-
tocol, using genome-wide data and combining strengths of
different methods and statistical tools. The proposed protocol
comprehensively describes several aspects of data analysis, starting
with data quality control and ﬁltering, followed by an analytic part
(statistical analysis using a number of available methods for epis-
tasis detection), and ending with a component on biological vali-
dation and interpretation of statistical ﬁndings. We illustrated this
protocol on a real-life data application for Alzheimer’s disease (AD)
(2259 patients and 6017 controls from France) (Fig. 1), hereby
providing the ﬁrst epistasis study of this magnitude for AD and
showing the advantages of viewing and analyzing data from
different angles. As a result, we identiﬁed a replicable epistasis
signal that contributes to the understanding of AD pathology.
2. Methods
2.1. Study subjects
In this study we used data collections of AD patients and healthy
controls (n ¼ 8276) of European ethnicity origin from 3 cities of
France: Bordeaux, Dijon, and Montpellier (Table 1). Details about
the ascertainment methods of the cohort (referred to as Fran-
ce_AD), as well as data quality control procedures are described
elsewhere (Lambert et al., 2009).
For replication and meta-analyses, we considered 5 indepen-
dent case and/or control data (Table 1). The Flanders-Belgian study
cohort (Belgium_AD, n ¼ 2370), was ascertained in the frame of a
prospective study of AD, as previously described in Bettens et al.
(2010). Clinical study protocol and the informed consent forms
for patient ascertainment were approved by the Ethics Committee
of the respective hospitals at the cohort sampling sites in Flanders-
Belgium. The genetic study protocols and informed consent forms
were approved by the Ethics Committees of the University of
Antwerp and the University Hospital of Antwerp, Belgium.
The ﬁrst USA cohort (USA_AD, n ¼ 5697) consisted of Caucasian
subjects collected at Mayo Clinic Minnesota in Rochester (574 cases
and 2350 controls), Mayo Clinic Florida in Jacksonville (870 cases
and 947 controls), or an autopsy-conﬁrmed series from the BrainBank at Mayo Clinic Florida (586 cases and 370 controls). The
characteristics of this cohort were previously described in Allen
et al. (2012). The AD diagnosis of clinical subjects and autopsied
AD subjects was made according to NINCDS-ADRDA criteria
(McKhann et al., 1984). All clinical controls had a clinical dementia
rating score of 0. All autopsied AD brains had Braak scores of 4.0.
Brains used as controls had Braak scores of 2.5 but often had
pathologies unrelated to AD. All clinical cases and controls from
Mayo Clinic Florida or Minnesota had ages of diagnosis or ages at
evaluation 59 years, respectively. All autopsied cases and controls
had ages at death 59 years. This study was approved by the
appropriate institutional review board and appropriate informed
consent was obtained from all participants.
The data for the second USA cohort (USA2_AD, n ¼ 1480), UK
(UK_AD, n ¼ 6925), and Germany (Germany_AD, n ¼ 1376) cohorts
(USA2_AD, UK_AD, and Germany_AD, respectively) were provided
by the Genetic and Environmental Risk for Alzheimer’s disease
Consortium (Harold et al., 2009). In total, 3333 cases and 1225
elderly screened control samples were recruited by the Medical
Research Council (MRC) Genetic Resource for AD (Cardiff University,
Kings College London, Cambridge University, and Trinity College
Dublin), the Alzheimer’s Research UK (ARUK) Collaboration (Uni-
versity of Nottingham, University of Manchester, University of
Southampton, University of Bristol, Queen’s University Belfast, the
Oxford Project to Investigate Memory and Ageing (OPTIMA), Oxford
University); Washington University, St Louis, United States; MRC
PRION Unit, University College London; London and the South East
Region AD project (LASER-AD), University College London; Compe-
tence Network of Dementia (CND) and Department of Psychiatry,
University of Bonn, Germany, and the National Institute of Mental
Health (NIMH) AD Genetics Initiative. All AD cases met criteria for
Table 1
Study subjects
AD cohorts Number of subjects Number of cases Mean age cases % Of women cases Number of controls Mean age controls % Of women controls
France_AD 8276 2259 74.4  8.6 64.9 6017 74.0  5.4 60.7
Belgium_AD 2370 1263 74.9  8.7 64.0 1107 65.0  13.7 56.0
USA_AD 5697 2030 79.3  7.6 39.0 3667 77.6  6.5 42.5
USA2_AD 1480 551 73.0  26.4 57.7 929 55.2  26.0 60.9
UK_AD 6925 2225 61.5  36.6 65.2 4700 50.9  13.3 53.0
Germany_AD 1379 555 72.1  11.3 63.8 824 56.4  8.1 51.5
Key: AD, Alzheimer’s disease.
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All elderly controls, were screened for dementia using the Mini-
Mental State Examination or Alzheimer’s Disease Assessment Scale-
Cognitive, were determined to be free from dementia at neuro-
pathologic examination orhad aBraak score of 2.5 or lower. A total of
5235 population controls were included in the 1958 British Birth
Cohort (1958BC) (http://www.b58cgene.sgul.ac.uk/), NINDS funded
neurogenetics collection at Coriell Cell Repositories (Coriell) (http://
ccr.coriell.org/), theKORAF4StudyWichmannet al., 2005, andHeinz
Nixdorf Recall Study (Birnbaum et al., 2009; Hillmer et al., 2008).
2.2. Genotyping
The France_AD cohort was genotyped with the with Illumina
Human 610-Quad BeadChips. The Belgium_AD cohort was geno-
typed only for markers rs6455128 and rs7989332 by Sequenom
MassARRAY assay using iPLEX Gold chemistry (Sequenom,
Hamburg, Germany), followed by MALDI-TOF mass spectrometry.
Polymerase chain reaction and extension primers were designed
using MassARRAY Assay Design software v3.0.2.0 (Sequenom).
Genotypes were called both automatically using MassARRAY Typer
software v4.0 (Sequenom) and manually, blinded for disease status.
The USA_AD cohort was genotyped only for markers rs6455128 and
rs7989332 using TaqMan (Applied Biosystems) technology, ac-
cording to established protocols. The GERAD samples (USA2_AD,
UK_AD, and Germany_AD cohorts) were genotyped by Illumina
610-quad chip (data for 3333 cases and 1225 elderly screened
controls) and by Illumina HumanHap550 Beadchip (data for 5235
population controls).
2.3. Statistical analysis
The proposed protocol for exhaustive GWAI analysis is sum-
marized in Fig. 1. In particular, for the France_AD discovery cohort
we ﬁrst applied Hardy-Weinberg disequilibrium (HWE) ﬁltering of
SNPs, using c2 test statistics and a Bonferroni-based nominal sig-
niﬁcance threshold of 0.05/567589 SNPs ¼ 8.6  108. SNPs
violating HWE in the control group were discarded. Then, we only
considered markers with MAF  0.05 and call rate 98%, based on
the case and/or control samples. Subsequently, omitting mito-
chondrial and sex chromosome markers, 474,893 SNPs were
retained for association analyses. All aforementioned QC steps, as
well as main effects association testing (classical trend test, df ¼ 1,
additive model) were performed with the SVS Version 7.5 software
(Golden Helix, Inc).
Before exhaustive genome-wide epistasis screening (Fig. 1), the
retained 474,893 SNPs were linkage disequilibrium (LD) pruned by
considering sliding windows of size 50 (the number of markers
used for LD testing at a time) with window increments of 1
marker, and setting the LD r2 threshold to 0.75 (for any pair of
markers under testing whose r2 > 0.75, the ﬁrst marker of the pair
was discarded), as implemented in SVS Version 7.5. The LD
pruning further reduced the number of markers to 312,480 SNPs.
For the genome-wide epistasis screening in the selected set ofSNPs, we used an adapted version of BOOST (BOolean Operation-
based Screening and Testing) (Wan et al., 2010) that uses logistic
regression analysis (c2 tests with maximally df ¼ 4, codominant
model) and allows for missing genotypes. All BOOST test results
were Bonferroni corrected for multiple testing by the number of
performed tests (i.e., the number of pairs of 312,480 SNPs ¼
312,480  [312,4801]/2 ¼ 48,821,718,960). The signiﬁcant SNP-
pairs were analyzed in more detail using logistic regression anal-
ysis in R 2.15.1, allowing the investigation of age (age when the
examination of the study participants was conducted), sex, and
APOE (apolipoprotein E) AD risk allele (ε4) as potential con-
founders (model: glm (y w SNP1 þ SNP2 þ covariates þ SNP1 
SNP2, family ¼ binomial [link ¼ “logit”])), if applicable. Consis-
tency of signiﬁcant epistasis results was veriﬁed by ﬁrst restoring
the LD structure in the genomic regions surrounding the SNPs of a
signiﬁcant pair and by selecting SNPs  0.5 Mb upstream and
downstream of the SNP pair for follow-up analysis with model-
based multifactor dimensionality reduction (MB-MDR) (Cattaert
et al., 2011) version 2.7.5, correcting for main effects as recom-
mended by Mahachie John et al. (2012) and using a permutation-
based step-down MaxT approach to control the family-wise error
rate to 0.05 (Cattaert et al., 2011). Unlike BOOST, MB-MDR is an
intrinsic nonparametric data mining method that avoids making
assumptions about epistasis models and overcomes some of the
hurdles of classical regression-based modeling, yet has similar
power performances to BOOST (Van Steen, 2012). We also created
synergy disequilibrium plot (Anastassiou, 2007; Watkinson and
Anastassiou, 2009) for SNPs, thus appearing in the signiﬁcant
interaction, and 10 upstream and downstream neighboring SNPs.
Replication analysis of interesting pairs was based on 5 inde-
pendent case and/or control data sets, as described previously. The
analysis involved logistic regression models assuming a codomi-
nant model of inheritance (mimicking BOOST) and accounting for
sex, age, and/or APOE only when statistical evidence for their
confounding effect was shown (R 2.15.1). Evidence for confounding
effects was based on the existence of signiﬁcant associations with
both disease status (AD) and the SNP pair under investigation. In
addition, multilocus genotype effect sizes of each of eight 2-locus
genotypes versus a reference multilocus genotype (00) were
estimated via a multilocus genotype (MLG) association analysis.
Here, 0 represents a major allele homozygote, 1 represents a
heterozygote, and 2 represents a minor allele homozygote sce-
narios. MLG is equivalent to a 2-order logistic regression analysis
with codominant coding for main effects. To increase the power of
the MLG association analysis, we combined the discovery and
replication cohorts in a meta-MLG analysis using random effect
models (DerSimonian-Laird estimator) or ﬁxed effect models
when no evidence for heterogeneity between studies could be
detected (assessed by the Q test for heterogeneity; rma function in
R library metafor). A smaller meta-analysis based p-value
compared with the corresponding discovery cohort based p-value
was considered as evidence for replicable epistasis. Finally, to
assess the biological role of identiﬁed statistical epistasis, we used
the IPA software (Ingenuity Systems, Inc).
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To investigate potential biological interaction between
KHDRBS2/CRYL1 gene pair, we evaluated correlation of brain
expression levels for these genes. The expression levels were ob-
tained from an autopsied cohort, which was assessed in a recently
published brain expression genome-wide association study, DASL
microarray expression data. A detailed description of the adopted
methodology is given elsewhere (Allen et al., 2012; Zou et al., 2012)
(Supplementary Note 2). In these analyses, KHDRBS2 level was the
outcome variable and CRYL1 was included as the independent
variable. Additional covariates that were included to correct for
technical or biological variables were APOE epsilon 4 dosage, age at
death, sex, polymerase chain reaction plate, RIN, (RIN RINmean)2,
as well as expression levels of genes that are speciﬁc for the main 5
cell types present in the central nervous system, namely ENO2 for
neurons (ILMN_1765796), GFAP for astrocytes (ILMN_1697176),
CD68 for microglia (ILMN_2267914), OLIG2 for oligodendrocytes
(ILMN_1727567), and CD34 for endothelial cells (ILMN_1732799).
We also used next-generation RNA sequence (RNAseq) data of
temporal cortex expression levels of 94 AD subjects to perform
additional correlation analysis between KHDRBS2 and CRYL1. These
data are based on 51 base-pair paired end RNAseq performed in
triplicate fashion on Illumina HiSeq instruments. We retrieved
expression levels of KHDRBS2, CRYL1, as well as the genes used as
covariates in the multivariable linear regression models (namely
ENO2 for neurons, GFAP for astrocytes, CD68 for microglia, OLIG2 for
oligodendrocytes, and CD34 for endothelial cells). For the analysis
log2 (gene counts) were used; KHDRBS2 levels were the outcome
variable and CRYL1 was included as the independent variable.
Additional covariates that were included to correct for technical or
biological variables were APOE epsilon 4 dosage, age at death, sex,
ﬂow cell, RIN, (RIN  RIN mean)2, as well as expression levels of
genes that are speciﬁc for the main 5 cell types.
2.5. Expression quantitative trait loci association analysis
We performed expression quantitative trait loci (eQTL) associa-
tion analysis (linear regression, additive model) to investigate
whether the discovered interacting SNPs, rs6455128, and rs7989332
regulate expression of KHDRBS2 and CRYL1 genes or other genes in
the proximity of 1 Mb from them. Analyses were done either in the
cerebellum or temporal cortex brain samples of the autopsied AD
subjects and non-AD subjects with other pathologies as described
previously (Zou et al., 2012). In the 2 targeted genomic regions, 20
transcripts (KHDRBS2: NM_152688.1, TPTE2: NM_130785.2, TPTE2:
NM_199254.1, MPHOSPH8: NM_017520.2, PSPC1: NR_003272.1,
ZMYM5: NM_001039650.1, ZMYM5: NM_001039649.1, GJA3:
NM_021954.3, GJB2: NM_004004.4, GJB6: NM_006783.2, CRYL1:
NM_015974.2, IFT88: NM_175605.3, IFT88: NM_006531.3, IL17D:
NM_138284.1, N6AMT2: NM_174928.1, XPO4: NM_022459.3, LATS2:
NM_014572.2, SAP18: NM_005870.3, MRP63: NM_024026.4, andFig. 2. Results for the exhaustive epistasis screening of epistasis associated with AD. The in
analysis, corrected for multiple testing, adjusted for confounders), MAFs and corresponding
Alzheimer’s disease; MAFs, minor allele frequencies; SNPs, single-nucleotide polymorphismZDHHC20: NM_153251.2) were detected with a total of 22 probes.
Both interacting SNPs were tested for association with the transcript
levels measured by these 22 probes in 4 types of analyses: (1) tem-
poral cortex AD subjects only; (2) all temporal cortex samples
including AD and non-AD subjects; (3) cerebellum AD subjects only;
and (4) all cerebellum samples including AD and non-AD subjects.
3. Results
3.1. Exhaustive genome-wide epistasis screening
The adapted BOOST method (codominant model) applied to the
QC-positive and LD-pruned set of markers (312480 SNPs) in the
France_AD cohort highlighted 3 signiﬁcant SNP-SNP interactions
with AD. Two of these, rs439401/rs405509 and rs439401/
rs8106922 had associated p-values pBonferroni-corrected ¼ 1.4  108
and pBonferroni-corrected ¼ 3.1  104, respectively. These variants are
located in the APOE gene region (19q13.32), although none of them
are in LD (r2 ranged: 0.019e0.62). The involved SNPs demonstrated
highly signiﬁcant main effects (rs439401: p ¼ 1.7  1032,
rs405509: p ¼ 5.9  1021, rs8106922: p ¼ 1.4  1028; uncorrected
p-values for trend test, df ¼ 1, additive model). When adjusting the
analysis for age, sex, and the ε4 AD-risk allele of APOE using logistic
regression (codominant model) the identiﬁed interactions became
insigniﬁcant (pBonferroni-corrected > 0.05 for both interactions). A
detailed investigation showed that APOEwasmostly responsible for
exaggeration of these signals. The third SNP pair signiﬁcantly
associated with AD and identiﬁed by BOOST involved rs6455128
(6q11.1, intron of the KHDRBS2 gene) and rs7989332 (13q12.11,
intron of the CRYL1 gene) (pBonferroni-corrected ¼ 0.044). No main ef-
fects for these SNPs were detected (rs6455128: p ¼ 0.23,
rs7989332: p ¼ 0.66; uncorrected p-values) (Fig. 2, Supplementary
Fig. 1). The rs6455128-rs7989332 interaction became even more
signiﬁcant (pBonferroni-corrected¼ 0.006) after adjusting it for age, sex,
and APOE as before. We restored the LD structure in the regions
surrounding rs6455128 and rs7989332 (0.5 Mb upstream and
downstream) and considered a total of 108 SNPs from 6q11.1 and
219 SNPs from 13q12.11 for a detailed MB-MDR epistasis analysis.
MB-MDR gives similar power performances as BOOST but suffers
less from harmful multicollinearity (Van Steen et al., 2002) induced
by even moderate LD patterns or increased false positive rates
because of LD (Moore et al., 2007). The pair rs6455128/rs7989332
was found to be the only signiﬁcant interaction identiﬁed by MB-
MDR in the selected region (p ¼ 0.005; additive model, step-
down MaxT corrected). For additional supporting results see
Supplementary Fig. 2.
3.2. Replication analysis for rs6455128 and rs7989332 interaction
Replication analysis for AD-associated SNP pair rs6455128/
rs7989332 was performed using 5 independent case and/or control
data sets: from Belgium (Belgium_AD), USA (USA_AD andformation about the interacting SNPs including p-value of association with AD (BOOST
main effects (uncorrected for multiple testing p-values) are shown. Abbreviations: AD,
s.
Fig. 3. Association of MLG(11) of the SNP-pair rs6455128/rs7989332 with AD: results
of the ﬁxed effect (RF) meta-analysis in the discovery cohort (France_AD) and 5
replication cohorts (USA_AD, USA2_AD, Belgium_AD, UK_AD, and Germany_AD). FE
ModeleFixed effect model; MLG(11)emulti locus genotype for rs6455128 (A/C) and
rs7989332 (A/C). Abbreviations: AD, Alzheimer’s disease; SNPs, single-nucleotide
polymorphisms.
Table 2
Results of multiple linear regression analysis depicting associations between brain
levels of the KHDRBS2 and CRYL1 genes
Brain samples type b 95% CI p
All temporal cortex samples 0.19 0.08 to 0.30 0.0006
Temporal cortex samples of
AD subjects
0.09 0.24 to 0.06 0.24
Temporal cortex samples of
non-AD subjects
0.32 0.16 to 0.48 0.0001
All cerebellum samples 0.23 0.13 to 0.34 <0.0001
Cerebellum samples of AD
subjects
0.32 0.17 to 0.46 <0.0001
Cerebellum samples of non-AD
subjects
0.12 0.03 to 0.28 0.12
Dependent variableeKHDRBS2 (ILMN_1658237), independent variableeCRYL1
(ILMN_1714397). Illumina DASL probe IDs are shown in parentheses. See correlation
plots in Supplementary Fig. 4 for more details. Bold values indicate 0.0001 is the
minimal p-value number the StatsDirect outputs.
Key: AD, Alzheimer’s disease; 95% CI, 95% conﬁdence interval.
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cohorts, MAFs for rs6455128 and rs7989332 ranged from 0.170 to
0.182 and 0.280 to 0.304, respectively, and no deviations from HWE
in controls were observed (Supplementary Table 1). Main effect on
AD was detected only for rs7989332 (uncorrected p ¼ 0.01) in
Belgium_AD cohort. The differences in distributions of the 2-locus
genotypes for rs6455128 and rs7989332 in cases and controls in
the discovery and replication cohorts are presented in
Supplementary Fig. 3. Whereas the age, sex, and APOE adjusted
logistic regression-based p-value for the pair rs6455128/rs7989332
was p ¼ 1.3  1013 in the discovery data (France_AD), it was 0.036
in the Germany_AD replication cohort. No signiﬁcant associations
were found in USA_AD, USA2_AD, Belgium_AD, and UK_AD cohorts.
Notably, no statistical evidence was found for sex, age (dichoto-
mized by the overall median of 66 years), and APOE to confound the
identiﬁed interaction in the Germany_AD cohort. These factors did
not signiﬁcantly associate with the multilocus genotype classes of
the SNP-pair rs6455128/rs7989332 (p ¼ 0.32 for age and pz 1 for
both sex and APOE; performed on 536 cases and 388 controls, for
which information about sex, age, and APOE was available).
In line with a composite hypothesis, for which main effects and
interaction effects are tested jointly, we performed a MLG associ-
ation analysis, which quantiﬁes effect sizes of each of 8 multilocus
genotypes derived from rs6455128/rs7989332 (0emajor allele ho-
mozygote, 1eheterozygote, and 2eminor allele homozygote)
versus the reference category (00ehomozygous for the major al-
leles). In the discovery France_AD cohort, the analysis revealed 4
signiﬁcant MLG effects (MGL(10): OR ¼ 1.23[1.06e1.42], p ¼ 0.005,
MGL(12): OR¼ 0.53[0.36e0.77], p¼ 9.6104, MGL(21): OR¼ 0.54
[0.33e0.90], p ¼ 0.017, and MLG(22): OR ¼ 6.17[2.80e13.12], p ¼
6.5  106) (Supplementary Table 2). Meta-MLG analysis (ﬁxed
effect model, Q test for heterogeneity: pq ¼ 0.097 for MLG(10), pq ¼
0.124 for MLG(12), pq ¼ 0.104 for MLG(21), and pq ¼ 0.091 for
MLG(22)) supplementing the discovery with 4 replication cohorts
did not make these effects stronger as we could not see improve-
ment of the pooled test statistics and the corresponding p-values as
compared with those for the discovery cohort. However, the meta-
analysis highlighted the AD-protective effect of the MLG(11)
(pooled OR ¼ 0.86[0.78e0.94]; pooled p ¼ 0.002, pq ¼ 0.836) that
was insigniﬁcant in the discovery cohort (Fig. 3).3.3. Transcriptome analysis for the gene-pair KHDRBS2/CRYL1
We investigated associations between brain expression levels
(transcriptome analyses) of KHDRBS2 (the probe IDeILMN_1658237)
and CRYL1 (the probe IDeILMN_1714397) genes in the autopsied
cohort of AD subjects and subjectswith other brainpathologies (non-
AD subjects) using regression modeling (Table 2, Supplementary
Fig. 4). In the DASL microarray expression data, there was signiﬁcant
negative linear association between KHDRBS2 and CRYL1 levels in
both the temporal cortex (b ¼ 0.19, p ¼ 0.0006) and cerebellar
measurements (b ¼ 0.23, p < 0.0001) from all subjects. When the
diagnostic groups were assessed separately, the temporal cortex
correlations appeared tobedrivenby thenon-ADsubjects (b¼0.32,
p¼ 0.0001), whereas the cerebellar resultswas signiﬁcant only in the
AD subjects (b ¼ 0.32, p < 0.0001). Nevertheless, the direction of
associations was consistent between the AD and non-AD subjects for
both brain regions, with overlapping 95% conﬁdence interval for the
estimated effect sizes. In the RNAseq data, signiﬁcant positive corre-
lations between KHDRBS2 and CRYL1 transcripts levels in the tem-
poral cortex of AD subjects were observed.
3.4. eQTL association analysis for rs6455128 and rs7989332
The eQTL analysis of the discovered interacting SNPs, rs6455128
and rs7989332,with the expressionofKHDRBS2 andCRYL1 transcripts
in the temporal or cerebellum brain regions did not show signiﬁcant
association (p-value varied between 0.20e0.89 for rs6455128 and
between 0.15e0.97 for rs7989332). Similar analysis in transcripts of
genes that residewithin 1Mb from either KHDRBS2 or CRYL1 revealed
signiﬁcant association of the GJB2 NM_004004.4 gene transcript
(probe IDeILMN_1769388) with rs7989332 in temporal cortex from
the combined set of AD and non-AD subjects (pBonferroni-corrected ¼
0.0352). There were also nominally signiﬁcant associations with
temporal cortex levelsof thisgene inADsubjectsonlyand incerebellar
levels in all subjects including AD and non-AD subjects
(Supplementary Table 3). Furthermore, levels of another nearby con-
nexin familygene,GJB6, showednominal associationswith rs7989332
in the temporal cortex of AD subjects (Supplementary Table 3).
4. Discussion
AD (OMIM #104300) is a complex, progressive neurodegener-
ative disease where dementia symptoms gradually worsen over
years. The disease is characterized by the neuropathologic ﬁndings
of neuroﬁbrillary tangles and amyloid plaques that accumulate in
vulnerable brain regions (Sennvik et al., 2000). It is a highly
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attributed to genetic factors (the most important being related to
APOE), possibly modulated by environmental factors (Bettens et al.,
2013). A number of epistasis signals between candidate genes for
AD were reported (summarized in Supplementary Table 3), how-
ever, only a few interactions were replicated in independent data.
To our knowledge, no exhaustive genome-wide epistasis screening
has been conducted for AD before. In this study, we outlined an
exhaustive GWAI analysis strategy to identify epistasis with a po-
tential relevant role to AD.
Exhaustive epistasis screening revealed the signiﬁcant AD-
associated SNP-SNP interaction rs6455128/rs7989332 (from
6q11.1 and 13q12.11, respectively), that did not appear to be inﬂu-
enced by the potential confounders sex, age, and APOE. This sta-
tistically signiﬁcant interaction effect was also highlighted using
replication cohorts and via meta-MLG analysis. The interacting
SNPs, rs6455128 and rs7989332, are located in the intronic parts of
the KHDRBS2 and CRYL1 genes, respectively.
At onehand,KHDRBS2 (KHdomain containing, RNAbinding, signal
transduction associated 2) is involved in regulation of signal trans-
duction and transcription, and its function has been investigated by
studies of its ortholog, Slm1, in Saccharomyces cerevisiae. Slm1, binds
signaling molecules, such as phosphatidylinositol 4,5-bisphosphate
(PIP2) at the inner plasma membrane. Its activity is regulated by heat
stress and it inﬂuences downstream cellular events, including mod-
ulation of the actin cytoskeleton, and nutrient transport with impli-
cations for cell growth and response to stress. Slm1 also interactswith
calcineurin and inﬂuences sphingolipid metabolism (reviewed in
Dickson, 2008). Thus, changes in levels of KHDRB2 could conceivably
inﬂuence both levels and functions of many other downstream genes
involved in cellular growth and response to stress. Recently, Slm pro-
teins were shown to interact with and activate the kinase complex
TORC2 (target of rapamycin kinase 2 complex), as a result of plasma
membrane stress by stretching (Berchtold et al., 2012). Chronic inhi-
bition of the TOR pathway reduced brain amyloid b and cognitive
deﬁcits in a mouse model of AD, possibly via upregulation of heat-
shock proteins (Pierce et al., 2012). These ﬁndings suggest a potential
linkamongKHDRBS2(Slm1ortholog), TOR,andheat-shockproteins in
ADpathogenesis.On theotherhand, theCRYL1 (crystallin, lambda1) is
a structural protein in lens and also has enzymatic activity (catalyzes
the dehydrogenation of L-gulonate into dehydro-L-gulonate in the
uronate pathway, an alternative glucose metabolic pathway, ac-
counting for about 5%of daily glucose catabolism). Intriguingly, CRYL1
belongs to the family of crystallins, many of which function as small
heat-shock proteins involved in stress-protection (Wistow, 2012). It is
therefore tempting to speculate a functional link between KHDRBS2
and CRYL1 along the cellular stress-TOR-heat-shock protein axis.
The fact that we were not able to show signiﬁcant inﬂuence of
the discovered variants, rs6455128 and rs7989332, on the expres-
sion levels of KHDRBS2 and CRYL1 genes in temporal cortex and
cerebellum brain regions does not exclude the possibility of an
interaction between these genes that may occur via other mecha-
nisms. Intriguingly, transcriptome analysis of KHDRBS2 and CRYL1
assessed by 2 approaches (DASL microarray data and RNAseq data)
revealed nominally signiﬁcant, though opposite directions for cor-
relations between brain levels of these genes in temporal cortex
samples. There could be several explanations for this. First, the
negative correlations in the microarray data were observed in all
tests, except temporal cortex of AD subjects and cerebellum of non-
AD subjects where there was no statistical signiﬁcance. It is
therefore plausible that RNAseq, as a more sensitive approach, is
picking up on a correlation that is in the opposite direction in this
brain region of ADs compared with other regions and subjects.
Temporal cortex is typically one of the most pathologically affected
regions in AD. If replicated, such opposing correlations of gene pairsin affected brain regions versus unaffected regions and/or in non-
AD subjects could have biologic relevance. Second, it should be
kept in mind that our RNAseq analysis assesses whole gene levels
whereas DASL expression microarrays measure levels of speciﬁc
exons and transcripts. Thus, opposing expression changes in the
exon (or speciﬁc transcript) versus whole gene levels can lead to
seemingly contradictory ﬁndings between the 2 methods. Future
studies should assess non-ADs as well as cerebellum with RNAseq
approaches, in addition to comparing speciﬁc exon levels with DASL
versus other methods. Follow-up functional studies are needed to
investigate the relationships between KHDRBS2 and CRYL1.
The discovered interacting variants, rs6455128 and rs7989332,
may also inﬂuence expression of other genes in close proximity to
KHDRBS2 and CRYL1. Particularly, rs7989332 was found to be
associated with the expression levels of the GJB2 (gap junction
protein, beta 2, 26 kDa) gene transcript. GJB2 is a gene from the
connexin family, which resides nearby CRYL1 on chromosome 13.
Nominally signiﬁcant association between GJB2 and CRYL1 levels in
temporal cortex of all subjects (AD and non-AD subjects), but not
with KHDRBS2 was also found in our study (p ¼ 0.02). These ﬁnd-
ings suggest that there may be regulatory variants near or within
CRYL1, which inﬂuence levels of the connexin family genes at this
locus. Although this intriguing idea requires replication, we can
only guess about its biological relevance to the epistatic variant pair
near CRYL1 and KHDRBS2.
5. Conclusion
This is theﬁrst epistasis study of thismagnitude for AD. Adopting
an exhaustive epistasis analysis strategy using genome-wide SNP
data has resulted in identiﬁcations of previously unreported SNP-
SNP interactions, with plausible biological underpinnings. A repli-
cation analysis strategyadapted to the epistasis detection context, as
well as a meta-analytic approach, conﬁrmed our ﬁndings. These
results are promising, given the theoretical sample sizes needed to
achieve power levels as theyare generally accepted in genome-wide
main effects studies. The conducted exhaustive epistasis screening
did not conﬁrm previously reported AD-associated epistasis signals
(summarized in Supplementary Table 4). We believe that in most
cases this is because of an elevatedmultiple testing burden (data not
shown). Also, in the presence of highly complex networks of
biochemical processes and genetic heterogeneity, is it really
reasonable to assume replication at the marker level? Should
replication not be established at the gene and/or pathway level
instead? How can standard meta-analysis techniques be adapted to
better accommodate nonparametric data-mining approaches for
epistasis discovery? How to best perform an epistasis meta-analysis
that involves pooling results over studies obtainedviaquite different
analysis techniques, as currently the number of epistasis modeling
and testing strategies is still increasing? Therefore, work in progress
includes setting user-friendly and theory-supported guidelines for
replication analysis and meta-analysis in the context of epistasis
screening.Despite thework still ahead, thepresentworkoffers aﬁrst
roadmap for exhaustive epistasis screening efforts and has provided
unprecedented leads of biological and clinical importance to AD
research.
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